NOW ACCEPTING PRADAXA AND XARELTO CASES: Representing Hundreds of Victims of Blood Thinner Drugs Nationwide

NOW ACCEPTING PLAVIX, PRADAXA AND XARELTO CLAIMS NATIONWIDE

Plavix, Pradaxa and Xarleto May Cause Bleeding, Including Gastrointestinal, Cerebral Hemorrhaging, Stomach Ulcers, Heart Attacks, Strokes, Thrombotic Thrombocytopenic Purpora (TTP) and death.
Plavix, Pradaxa and Xarleto, popular drugs used to prevent blood clots in people at risk for a heart attack, has been linked to some serious side effects, especially bleeding. In addition to gastrointestinal and cerebral hemorrhaging, Plavix, Pradaxa and Xarleto bleeding can include eye (conjunctival, ocular, retinal) bleeding, musculoskeletal bleeding, fatal intracranial bleeding, respiratory tract bleeding, and skin bleeding, according to its label. As a matter of fact, bleeding, including life-threatening and fatal bleeding, is the most commonly reported Plavix, Pradaxa and Xarleto side effect.

CONTACT US NOW FOR MORE INFORMATION ABOUT YOUR RIGHTS

 

Other Plavix, Pradaxa and Xarleto side effects include Thrombotic Thrombocytopenic Purpura or TTP. TTP is a rare blood condition that causes blood clots to form in small blood vessels throughout the body. The blood clots can cause serious problems if they block the blood vessels and limit blood flow to the brain, kidneys, or heart.

For years, it was thought the commonly prescribed Plavix, Pradaxa and Xarleto-aspirin combination would cause less bleeding than an alternative blood thinner, Warfarin. But recently, a study conducted by the U.S. Centers for Disease Control (CDC) and published in the Archives of Internal Medicine found the risk of hemorrhaging among Plavix, Pradaxa and Xarleto-aspirin patients was significantly higher than thought. While the CDC study did find that Warfarin was associated with a higher rate of bleeding than the Plavix-aspirin combo, the combination therapy did not do as well in that area as was expected. For both regimens, the number of hospital admissions because of bleeding was similar. And bleeding-related visits to emergency department visits were only 50 percent lower for those on the Plavix, Pradaxa and Xarleto-aspirin combo.

A common type of Plavix, Pradaxa and Xarleto bleeding is gastrointestinal bleeding. A recent study in the New England Journal of Medicine found that patients taking Plavix, Pradaxa and Xarleto are 12 times more likely to suffer recurrent ulcers and Plavix, Pradaxa and Xarleto gastrointestinal bleeding than those who received a combination of aspirin and a heartburn pill.

Proton Pump Inhibitors (PPIs), such as Prilosec Nexium, Prevacid, Aciphex, and Protonix, are often prescribed to reduce the risk of gastric bleeding from the Plavix, Pradaxa and Xarleto-aspirin combo. But it now appears that those drugs might not be appropriate for Plavix, Pradaxa and Xarleto users. That’s because Plavix does not have anti-clotting effects until it is converted or metabolized into its active form with the help of a liver enzyme called CYP2C19. But it is known that at least Prilosec blocks the CYP2C19 liver enzyme, thereby reducing the effectiveness of Plavix, Pradaxa and Xarleto. It is not know how other PPIs interact with Plavix, but the U.S. Food & Drug Administration has warned that Plavix should not be used with many PPIs.

The “Warnings and Precautions” section of the Plavix, Pradaxa and Xarleto label cautions that patients should discontinue Plavix, Pradaxa and Xarleto five days prior to elective surgery. In regards to transient ischemic attack or stroke, that section also warns that the much-used combination use Plavix, Pradaxa and Xarleto and aspirin in these patients was not shown to be more effective than Plavix, Pradaxa and Xarleto alone, but was shown to increase major bleeding. Plavix, Pradaxa and Xarleto is also contraindicated in patients with active pathological bleeding, including peptic ulcer or intracranial hemorrhage.

The Plavix, Pradaxa and Xarleto label advises doctors to counsel their patients that Plavix, Pradaxa and Xarleto will cause them to bruise and bleed more easily, and that it will take longer than usual to stop bleeding. Patients should report any unanticipated, prolonged, or excessive bleeding, or blood in their stool or urine.